Clinical Trials Browser

Nasopharyngeal Carcinoma × tislelizumab × 90 days × Clear all

NCT05211232 2026-05-29

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma